eGenesis’ genetically modified pig kidney transplant program reached preclinical proof-of-concept in a monkey model, and the company is in discussions with the FDA about what could be one of the first ever in-human kidney xenotransplant trials.
The US biotech said Wednesday that it edited the pig kidneys to knock out three genes involved in the synthesis of antibodies that can lead to hyperacute organ rejection. Seven human transgenes were added, and retroviruses native to the pig genome were turned off. The research was published in Nature.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.